Search Results
Your search for The ASCO matches 21412 pages
Showing 5701 - 5750Study Evaluates Residential Racial Segregation and NSCLC Treatment and Outcomes
Non–small cell lung cancer (NSCLC) accounts for 80% to 85% of cases of lung cancer; when it is diagnosed early, there is a 5-year survival rate of 50% to 80%. Black patients have a lower overall incidence of NSCLC than White patients but are more likely to be diagnosed at later stages. They also...
ASCO/Friends of Cancer Research Joint Position Statement Encourages Enrollment of Patients With Cancer in COVID-19 Vaccine Studies
Individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion, ASCO and Friends of Cancer Research (Friends) asserted in a joint position statement released today. To date, clinical trials...
Testing of Lymph Nodes for Breast Cancer Recurrence After Neoadjuvant Chemotherapy
A study published by Sharp et al in The Breast Journal suggests that some patients with breast cancer may be able to forgo certain testing procedures after neoadjuvant chemotherapy without increasing their risk of cancer recurrence. Prior studies on detecting whether breast cancer has spread to...
Study Explores Incidence Rates for Various Pediatric Cancers Across Age and Racial Groups
New research has uncovered substantial differences in the rates of childhood cancers when considering a single year of age rather than grouping several years together. The study, published by Marcotte et al in the journal Cancer, also found that minority children seem to have different risks than...
Neeraj Agarwal, MD, on Prostate Cancer: Androgen-Deprivation Therapy With Orteronel or Bicalutamide
Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses phase III data from the SWOG S1216 trial, which evaluated the clinical benefit of using androgen-deprivation therapy with either orteronel (or TAK-700, a CYP17 inhibitor) or bicalutamide in patients with newly...
Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses results from the phase III GeparNUEVO study, which investigated neoadjuvant durvalumab in addition to anthracycline/taxane-based neoadjuvant chemotherapy in patients with early triple-negative breast cancer (Abstract 506).
Lung Cancer Data From the 2021 ASCO Annual Meeting
On this episode, we’re looking specifically at data on lung cancer presented during the 2021 ASCO Annual Meeting.
Arnon P. Kater, MD, PhD, on CLL: Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab
Arnon P. Kater, MD, PhD, of the University of Amsterdam, discusses a primary analysis of the phase III GLOW study, which, for the first time, compared the efficacy and safety of fixed-duration ibrutinib plus venetoclax with chlorambucil plus obinutuzumab for first-line treatment of older patients...
Peter C. Black, MD, on Prostate Cancer Health-Care Disparities: Expert Perspective
Peter C. Black, MD, of the Vancouver Prostate Centre, University of British Columbia, reviews three studies on early detection and treatment of Black patients with prostate cancer: a large-scale analysis of genomic profiling; the use of PSA screening; and integrating a patient-specific genomic...
Survivors of Early-Stage Breast Cancer Face Broad Range of Symptoms and Concerns
Patients with early-stage breast cancer may be at low risk of dying of their disease, but they experience a high burden of physical and psychological symptoms long after their treatment has ended, according to data presented during the 2021 American Society of Breast Surgeons Annual Meeting.1...
FDA Oncology Center of Excellence Launches National Black Family Cancer Awareness Week
The U.S. Food and Drug Administration (FDA)'s Oncology Center of Excellence (OCE) has announced its inaugural National Black Family Cancer Awareness Week, which is taking place from June 17 through June 23, 2021. Throughout the week, the agency’s social media platforms will serve as the hub for...
Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response
Keith W. Pratz, MD, of the University of Pennsylvania, discusses the outcomes of patients with acute myeloid leukemia who took part in the VIALE-A trial and were treated with venetoclax and azacitidine. The patients had achieved both composite complete remission and measurable residual disease of...
Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab
Efstathios Kastritis, MD, of the University of Athens, discusses updated phase III results from the ANDROMEDA study of patients with newly diagnosed light chain amyloidosis. The trial further supports the use of daratumumab plus VCd (bortezomib, cyclophosphamide, and dexamethasone), which was shown ...
Novel Monoclonal Antibody Emerges as Potential First-Line Standard in Nasopharyngeal Cancer
A new first-line standard of care may be emerging for recurrent or metastatic nasopharyngeal carcinoma, based on the findings of the global phase III JUPITER-02 trial presented at the 2021 ASCO Annual Meeting by investigators from China.1 In the study, toripalimab, an anti–PD-1 monoclonal antibody, ...
Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL/SLL: ALPINE Trial
Zanubrutinib—a second-generation Bruton's tyrosine kinase (BTK) inhibitor—significantly improved response rates and delayed disease progression as compared to the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...
ASCO Releases Rapid Guideline Recommendation Update for Patients With High-Risk, HER2-Negative, Germline BRCA–Mutated Breast Cancer
A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk, early-stage, HER2-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations update the 2020...
FDA Approves Avapritinib for Advanced Systemic Mastocytosis
On June 16, the U.S. Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor avapritinib (Ayvakit) for adult patients with advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and...
Nearly Half of Surveyed Patients With Gynecologic Cancer Report Experiencing Financial Toxicity
In a new study designed to provide a more comprehensive picture of how a diverse cohort of patients with gynecologic cancer are affected by financial distress, nearly half reported financial toxicity, which was associated with economic cost-coping strategies. These findings were reported by Esselen ...
Geoffrey J. Lindeman, MBBS, PhD, on Breast Cancer: Venetoclax and Fulvestrant in ER-Positive, HER2-Negative Disease
Geoffrey J. Lindeman, MBBS, PhD, of Peter MacCallum Cancer Centre, discusses results from the phase II VERONICA study, which compared venetoclax plus fulvestrant with fulvestrant alone in women with estrogen receptor–positive, HER2-negative, locally advanced or metastatic breast cancer who...
Nicholas J. Short, MD, on ALL: Ponatinib Plus Blinatumomab May Help Patients Avoid Transplants
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses early results from a phase II study which showed that combining ponatinib and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia may prove to be an effective...
Ann S. LaCasce, MD, on Hodgkin Lymphoma: PET-Adapted Therapy for Bulky Disease
Ann S. LaCasce, MD, of Dana-Farber Cancer Institute, discusses results from the CALGB 50801 Alliance study, which showed that a PET scan–adapted approach may reduce the need for radiation treatment and may improve progression-free outcomes in patients with stage I/II bulky classic Hodgkin lymphoma...
Nadia Harbeck, MD, PhD, on Luminal Breast Cancer: Prognostic Impact of Recurrence Score, Endocrine Response, and Other Factors
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses first phase III results from a prospective high-risk cohort of patients with luminal breast cancer, which showed a good prognosis in some women with more than four positive lymph nodes and low recurrence scores. The study...
Sumanta K. Pal, MD, on Urothelial Carcinoma: Comparing Cisplatin and Gemcitabine With or Without Berzosertib
Sumanta K. Pal, MD, of City of Hope, discusses results from a phase II study that sought to determine whether adding berzosertib, a selective ATR inhibitor, to the standard upfront chemotherapy regimen of cisplatin with gemcitabine may improve outcomes in patients with metastatic urothelial...
Adjuvant Platinum vs Capecitabine in Patients With Basal Subtype Triple-Negative Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy
As reported in the Journal of Clinical Oncology and during the 2021 ASCO Annual Meeting by Ingrid A. Mayer, MD, and colleagues, the phase III ECOG-ACRIN EA1131 trial investigated the use of adjuvant platinum vs capecitabine in patients with basal subtype triple-negative breast cancer and residual...
Computational Tool Suggests Optimal Treatment for Patients With High-Grade Ovarian Cancer
A mathematical tool may help to examine how doctors may coordinate available treatments for high-grade serous ovarian cancer. Published by Gu et al in the Proceedings of the National Academy of Sciences, the new analysis showed that patients who can have complete debulking surgery first, with...
Expert Point of View: Henry Kuerer, MD, PhD, FACS
Henry Kuerer, MD, PhD, FACS, a cancer surgeon and researcher at The University of Texas MD Anderson Cancer Center, told The ASCO Post that although this study is not practice-changing, it does offer a potential option for patients. “The advantage of this technique is that the procedure takes just...
Ibrutinib/Venetoclax Provides Durable Remission for Patients With Newly Diagnosed CLL
The combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL). Findings from a single-institution phase II study were published by Nitin Jain, MD, and colleagues in JAMA Oncology and provide the longest ...
2021 ASCO Annual Meeting: Reports on Kidney, Esophageal, and Cervical Cancers
We’re continuing our coverage of Plenary presentations from the 2021 ASCO Annual Meeting, including research on adjuvant pembrolizumab for patients with renal cell carcinoma; novel treatment options for advanced esophageal squamous cell carcinoma; and adjuvant chemotherapy given after standard...
FDA Approves New Pediatric Indication for Technetium Tc 99m Tilmanocept Injection
The Lymphoseek (technetium Tc 99m tilmanocept) injection—a radiopharmaceutical agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsies—has been approved for pediatric use by the U.S. Food and Drug Administration (FDA). "This new indication opens the door...
Navigating the Post-Vaccine Pandemic
By now, most health-care workers have been vaccinated against COVID-19.* Physical immunity would appear to last for at least 6 months and probably longer. The physical pandemic for most oncologists is declining, with an end in sight. We are protected from the serious physical consequences of...
Telehealth Flexibilities Helping People Have Uninterrupted Access to Cancer Care Should Continue After the COVID-19 Pandemic
ASCO submitted comments to a House Ways and Means Health Subcommittee hearing titled “Charting the Path Forward for Telehealth.” The comments convey ASCO’s views on how telehealth can better serve individuals with cancer and the oncology professionals who care for them. During the COVID-19...
Senators Richard Burr and Ben Cardin Recognized as ASCO Congressional Champions for Cancer Care
ASCO has presented Senators Richard Burr (R-NC) and Ben Cardin (D-MD) with the annual Congressional Champion for Cancer Care Award in recognition of their ongoing commitment to legislation that improves the environment for cancer research, oncology practice, and the quality of care for patients....
New Study Shows Difficulty in Identifying Transgender Individuals Using EHR Data
In order to understand and eliminate disparities in cancer incidence and outcomes among transgender people, clinicians and researchers must have data. However, these data are very difficult to obtain because gender identity data are not routinely collected in oncology practice health records. A new ...
Two Memorial Sloan Kettering Experts Awarded for Pioneering Work
Memorial Sloan Kettering Cancer Center (MSK) recently announced that Larry Norton, MD, Senior Vice President, Office of the President; and Medical Director of the Evelyn H. Lauder Breast Center, has been elected to the American Academy of the Arts & Sciences, an honorary society that recognizes ...
Dual Immune Checkpoint Blockade With Nivolumab and Ipilimumab for Treatment of Malignant Pleural Mesothelioma
In recent years, immune checkpoint inhibitors in the treatment of mesothelioma have been a keen area of investigation for this immunogenic solid tumor. With recent publications, principally findings from CheckMate 743 by Baas et al1 (reviewed in this issue of The ASCO Post), combination immune...
Is High Tumor Mutational Burden Predictive of Immune Checkpoint Blockade Efficacy Across All Cancer Types?
In a letter recently published in The New England Journal of Medicine and reviewed in this issue of The ASCO Post, Rousseau and colleagues reported data on the spectrum of benefit from immune checkpoint blockade in hypermutated tumors.1 Indeed, the U.S. Food and Drug Administration (FDA) recently...
Carol L. Prives, PhD, FAACR, Receives 2021 AACR–G.H.A. Clowes Award for Outstanding Basic Cancer Research
The American Association for Cancer Research (AACR) presented Carol L. Prives, PhD, FAACR, with the 2021 AACR–G.H.A. Clowes Award for Outstanding Basic Cancer Research during the virtual AACR Annual Meeting 2021. Dr. Prives, the Da Costa Professor of Biology in the Department of Biological Sciences ...
Selected Poster Presentations From the NCCN 2021 Annual Conference
Although once again, the National Comprehensive Cancer Network® (NCCN®) 2021 Annual Conference could not take place on site in Orlando, researchers presented their work virtually in the form of almost 100 posters. The ASCO Post has summarized some that we found particularly interesting. Many...
The Brooklyn Cancer Center Announces New Chief of Hematology and Medical Oncology
The Brooklyn Cancer Center has named hematologist-oncologist Maxim Shulimovich, DO, as its new Chief of Hematology and Medical Oncology. His recruitment promises to lead the cancer center as a unified division to provide expert care and culturally sensitive services for patients with all types of...
Roswell Park Immunologist Promoted to Endowed Chair Role
Following a national search, Roswell Park Comprehensive Cancer Center has promoted Pawel Kalinski, MD, PhD, to Jacobs Family Endowed Chair of Immunology, Chief of the Division of Translational Immuno-Oncology, and Senior Vice President for Team Science. On staff at Roswell Park since 2017, Dr....
Pershing Square Sohn Cancer Research Alliance Awards $3.6 Million to Six Emerging Pioneers in Cancer Research
The Pershing Square Sohn Cancer Research Alliance has announced the winners of the 2021 Pershing Square Sohn Prize for Young Investigators in Cancer Research, awarded annually to cancer research scientists and physician-scientists based in the greater New York City area. The prize, totaling $3.6...
National Advocacy Organization, Children’s Cancer Cause, Invites Applications for 2021 Survivorship Champion’s Prize
The Children’s Cancer Cause is now accepting applications for its 2021 Survivorship Champion’s Prize. The annual award was established in 2020 to recognize a group, program, or institution making significant advances in programs and services to provide lifelong health maintenance for survivors of...
Data Analysis on Early-Onset Colorectal Cancer Sheds Light on the Rising Rates in Young Adults
In May 2021, the U.S. Preventive Services Task Force (USPSTF) announced that it was updating its recommendation for when individuals at average risk of colorectal cancer should begin screening. Echoing the recommendation from the American Cancer Society in 2018, the USPSTF now recommends that those ...
I Was Given a ‘Death Sentence’ at Just 17
A minor car accident I had with my mother when I was 17 probably saved my life. We were taken to the hospital for a routine checkup, and a subsequent chest x-ray found multiple nodules on my lungs. I underwent dozens of other imaging and blood tests, and finally, my pediatrician suggested my...
Medical Oncologist Gouri Shankar Bhattacharyya, MD, FRCP, Dies of COVID-19–Related Complications
The members of the oncology community who spend time and energy addressing the growing global cancer burden in low- and middle-income countries have a kind of selfless dedication beyond the scope of the profession itself. One such medical oncologist was Gouri Shankar Bhattacharyya, MD, FRCP, a...
Fox Chase Cancer Center’s Jennifer Barsky Reese, PhD, Receives New Investigator Award
Jennifer Barsky Reese, PhD, Associate Professor for the Cancer Prevention and Control Program at Fox Chase Cancer Center, was recently recognized with the New Investigator Award from the American Psychosocial Oncology Society (APOS). “I am extremely honored to get this award. This is a testament...
‘Radiation Is Not the Enemy’
“I want to make very clear that radiation is not the enemy,” Monika Metzger, MD, MSc, emphasized in discussing a study she led on the integration of brentuximab vedotin into the front-line treatment of pediatric patients with high-risk Hodgkin lymphoma. The study yielded excellent results while...
Adding Targeted Agent to Treatment Shows Significant Benefits in Pediatric Patients With High-Risk Hodgkin Lymphoma
Integrating the antibody-drug conjugate brentuximab vedotin into the front-line treatment of pediatric patients with high-risk Hodgkin lymphoma “facilitated significant reduction in radiation exposure and yielded excellent outcomes,” Monika Metzger, MD, MSc, Director for the Central and South...
Disease-Free Survival Benefit With Adjuvant Immunotherapy in Resectable Esophageal Cancer: Practice-Changing for All Patients?
The CheckMate 577 trial—reported in The New England Journal of Medicine by Kelly et al1 and reviewed in this issue of The ASCO Post—is the first global randomized controlled trial for patients with resectable esophageal cancer that showed a significant disease-free survival benefit for adjuvant...
Cabozantinib With Nivolumab for Metastatic Renal Cell Carcinoma: A New Front-Line Standard
The pace of clinical research in metastatic renal cell carcinoma is faster than ever. Over the past 5 years, we have seen data from six phase III clinical trials evaluating combination strategies with checkpoint inhibitors. The era began with data from CheckMate 214, evaluating nivolumab with...
